Ionis Pharmaceuticals
IONSIonis Pharmaceuticals is a commercial-stage biotechnology company specializing in RNA-targeted therapeutics.
Earnings
Next report
Aug 5, 2026 (In 3 weeks)Revenue estimate$190.4M
EPS estimate-$0.92
Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
Profile
Ionis Pharmaceuticals is a commercial-stage biotechnology company specializing in RNA-targeted therapeutics. The company leverages its proprietary antisense technology to discover and develop medicines that treat serious diseases by precisely modulating the expression of disease-causing genes. Its core value proposition lies in its industry-leading drug discovery platform and a robust pipeline focused on neurology, cardiometabolic diseases, and rare conditions.
Competitive position
A pioneer and leader in RNA-targeted therapeutics with a fully integrated commercial infrastructure and a dominant intellectual property estate in antisense technology.
GeographiesUnited States, European Union, Canada, China, Japan, Brazil
Customer segmentsPatients with rare diseases, Global pharmaceutical companies, Healthcare systems
Business modelProduct Sales, Licensing and Royalties, Collaborative R&D
SuppliersNucleotide building block suppliers, Contract Manufacturing Organizations (CMOs), Specialized laboratory equipment providers
CustomersSpecialty drug distributors, Hospitals and clinics, Global pharmaceutical licensees
CountryUnited States of America
Listed1991
Employees927.0
CEOBrett Monia
SectorHealthcare
IndustryBiotechnology
Websiteionispharma.com
FilingsSEC EDGAR
Questions, answered.
- What is Ionis Pharmaceuticals's market cap?
- Ionis Pharmaceuticals (IONS) has a market capitalization of $14.0B and trades on NASDAQ.
- What is Ionis Pharmaceuticals's revenue and profitability?
- Ionis Pharmaceuticals generated $1.1B in trailing twelve-month revenue with a net loss of $327.0M, representing a net margin of -30.9%. Gross margin stands at 98.4%, with free cash flow of -$1.3B. These figures are based on the Q1 2026 filing.
- Who are Ionis Pharmaceuticals's competitors?
- Ionis Pharmaceuticals's key competitors include Alnylam Pharmaceuticals, BridgeBio Pharma, Arrowhead Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Ionis Pharmaceuticals partner with?
- Ionis Pharmaceuticals's notable partners include AstraZeneca, Biogen, GSK, and others.
- Where is Ionis Pharmaceuticals headquartered?
- Ionis Pharmaceuticals is headquartered in United States of America and employs approximately 927 people. It has been publicly traded since 1991.
